Vulvar Cancer clinical trials at University of California Health

2 research studies open to eligible people

Showing trials for

  • Groningen International Study on Sentinel Nodes in Vulvar Cancer-III

    open to eligible females ages 18 years and up

    Vulvar cancer patients with SN-metastasis > 2mm will receive chemoradiation instead of an inguinofemoral lymphadenectomy.

    at UC Irvine

  • Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

    open to eligible people ages 18 years and up

    This phase II trial tests whether nivolumab in combination with cabozantinib works in patients with mucosal melanoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It works by blocking the action of an abnormal protein that signals tumor cells to multiply. This helps stop the spread of tumor cells. Giving nivolumab in combination with cabozantinib could prevent cancer from returning.

    at UCSF

Our lead scientists for Vulvar Cancer research studies include .

Last updated: